94 results about "Thyreoidin" patented technology

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, X1, X2, Y1, and Y2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

Provided herein are compounds, preferably thyroid hormone receptor beta, THRbeta, agonist compounds, compositions thereof, and methods of making the same, and methods of agonizing THRbeta, and methods for treating conditions mediated by THRbeta.

The present invention relates to thyroxine beta receptor selective agonist compounds, pharmaceutical compositions and uses thereof. Specifically, the invention relates to a compound as shown in a formula (I). The compound provided by the invention has excellent drug effect and / or specificity, and can be used for treating metabolism-related diseases.

The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.

The application discloses a construction method and application of an osteoarthritis cartilage organoid, and the method comprises the following steps: 1) mesenchymal stem cells are inoculated on a round bottom culture plate by a Micromass method, and are cultured in a chondrogenic induction culture medium containing dexamethasone, ascorbic acid and TGF-beta 3 for 10-18 days to form a transparent cartilage organoid; and 2) the transparent cartilage organoid is placed in an osteoarthritis induction culture medium containing dexamethasone, L-thyroxine, inflammatory factors (IL-1beta, IL-6 and TNF-alpha) and beta-glycerophosphate sodium for continuous culture for 5-10 days to obtain an osteoarthritis cartilage organoid; the model simultaneously presents multi-dimensional pathological characteristics such as matrix degeneration, hypertrophy, inflammation activation and vascularization trend, and can be used for osteoarthritis pathogenesis research, drug screening and cell treatment effect evaluation; the construction method is controllable and has good repeatability, and provides a reliable three-dimensional in-vitro model for osteoarthritis research.

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

Disclosed is a method for diagnosing a cancer health state, or a change in cancer health state in a patient, or for diagnosing a risk of the change or presence of a cancer in a patient, comprising determining, in a plasma sample from said patient, one or more biomarker values that correspond to transthyretin-containing complex structures, and assigning the patient as having or not having cancer, or having or not having a change in cancer health state, or having or not having a risk of cancer based on said biomarker values, wherein said cancer is preferably lung cancer (LC).

The present disclosure relates to the field of clinical detection technology, in particular, to the application of triiodothyronine autoantibody as a marker of thyroid dysfunction during cancer treatment. The present disclosure can help clinicians to judge the real thyroid function status of patients and improve the accuracy of diagnosis.

The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the TTR gene. Methods of using such RNAi constructs to treat or prevent cardiac disease, such as transthyretin-associated cardiomyopathy (ATTR-CM), are also described.

The present invention addresses the problem of providing a means for making it possible to detect transthyroxine (TTR) tetramers in a sample. The problem is solved by a step for forming a complex containing a TTR tetramer in a sample, a compound capable of binding to a thyroxine binding site of the TTR tetramer, an antibody capable of binding to a TTR monomer, and a labeling substance, and a step for measuring a signal generated by the labeling substance contained in the complex.

Provided are compounds having the following structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X 1 , X 2 , Q, R 1 , R 2 , and n are as defined herein. Such compounds are useful as thyromimetic agents and have utility for treating diseases such as neurodegenerative diseases and fibrotic diseases. Also provided are pharmaceutical compositions containing such compounds, as well as methods of their use and preparation.

Assessment of transthyretin amyloid cardiomyopathy (ATTR-CM) can be performed by calculating a cardiac pyrophosphate activity (CPA) measurement from single-photon emission computed tomography (SPECT) images. SPECT images obtained using 99mTechnetium-pyrophosphate as a radiotracer can be analyzed to calculate CPA. Scan-specific thresholds for abnormal myocardial activity are identified based on left ventricular blood pool (LVBP) radiotracer counts, then radiotracer activity in regions of the myocardium with abnormal myocardial activity is determined. Finally, a CPA measurement can be calculated as a function of the mean radiotracer counts in such regions over the maximal LVBP radiotracer activity multiplied by the volume of involvement (e.g., the volume of abnormal activity). This CPA measurement can then be used as an assessment of ATTR-CM.

The invention discloses a novel serum metabolite composition based on dried blood spot detection and elaborates application of the serum metabolite composition as a marker in preparation of a congenital hypothyroidism diagnostic reagent or kit. The serum metabolite composition comprises thyroxine, 2-piperidone and phosphorylcholine PC (14: 0 / 20: 4). The serum metabolite composition can be used for screening and diagnosing patients with the congenital hypothyroidism, and has the characteristics of low detection cost, good repeatability and relatively high sensitivity and specificity.

Compositions and regimens useful in treating type I citrullenemia are provided. The compositions include recombinant adeno-associated virus (rAAV) with a transthyretin enhancer and promoter driving expression of a human Argininosuccinate Synthase 1 (ASS1).

To provide an effective therapeutic method for TTR-associated diseases.SOLUTION: The present invention provides iRNA agents, for example, double-stranded iRNA agents, that target the transthyretin (TTR) gene, and methods of using such iRNA agents for treating or preventing TTR-associated diseases.SELECTED DRAWING: None

Immunotherapy for musculoskeletal disorders and conditions associated with transthyretin amyloidosis is provided.

Transthyretin (TTR) is a soluble protein involved in thyroxine and retinol transport in the body. Under certain conditions, the TTR protein adopts a misfolded, misassembled, and / or aggregated TTR conformation, which can be toxic and lead to transthyretin-mediated amyloidosis (ATTR). Provided herein, inter alia, are compositions (e.g., pharmaceutical compositions) containing anti-TTR antibodies or antigenic fragments thereof, and related articles of manufacture. Further provided herein, inter alia, are methods for treating or preventing ATTR using the pharmaceutical compositions described herein.

The technical scheme provided by the invention is application of quercetin in aquaculture, in particular to application of quercetin in preparation of drugs and / or feeds for preventing and treating thyroxine disorder and / or serotonin disorder of aquatic animals. The invention has the beneficial technical effects that the natural plant component quercetin which is originally applied to medicines and health care products for people is expanded to be applied to the field of aquatic animals, so that the nutrition required by the aquatic animals can be provided, the effect of regulating thyroid hormone and / or serotonin disorder of the aquatic animals can be achieved, the quercetin is used for replacing hormone medicines, and the health care effect is good. The method is friendly to an ecological chain, and green, cyclic and sustainable development is realized.

Hyperthyroid diarrhea refers to hyperthyroid diarrhea, which is mostly intractable diarrhea, due to excessive thyroid hormone causing increased intestinal peristalsis excitability and diarrhea when the thyroid function is increased, which is caused by endocrine metabolic disorder leading to gastrointestinal function disorder. The present application studies and observes the treatment effect of kaempferol coupling derivative JC-1 on diarrhea of hyperthyroid model mice, and provides a new drug treatment option for diarrhea type colon dysfunction.

To provide compositions and methods for treating pathological conditions and diseases, such as a TTR amyloidosis, in a mammal caused by expression of a transthyretin (TTR) gene.SOLUTION: There is provided a double-stranded ribonucleic acid (dsRNA) for inhibiting transthyretin (TTR) expression, where the dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region complementary to a portion of an mRNA encoding transthyretin (TTR), where the region of complementarity is less than 30 nucleotides in length, and where the antisense strand comprises 15 or more contiguous nucleotides of a specific sequence.SELECTED DRAWING: None

The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine (“T3”) serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.

Described herein are methods for treating transthyretin (TTR) amyloidosis with Compound 1 in a subject comprising certain mutations in the TTR protein (Compound 1). The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.

The present invention provides novel non-invasive methods for detecting misfolded transthyretin (TTR) proteins, and for diagnosing and monitoring amyloidosis and related disorders.

Pharmaceutical compositions for treating human subjects suffering from or at risk of developing a TTR-related disorder are provided. [Solution] A pharmaceutical composition comprising a double-stranded RNAi agent administered at a fixed dose of approximately 50 mg, the double-stranded RNAi agent comprising a sense strand complementary to an antisense strand, wherein the sense strand comprises the nucleotide sequence 5'-usgsggauUfuCfAfUfguaaccaaga-3' (SEQ ID NO: 10), and the antisense strand comprises the nucleotide sequence 5'-usCfsuugGfuuAfcaugAfaAfucccasusc-3' (SEQ ID NO: 7), wherein a, c, g, and u are 2'-O-methyl (2'-OMe) A, C, G, or U; Af, Cf, Gf, and Uf are 2'-fluoro A, C, G, or U; and s is a phosphorothioate linkage.

The present application relates to the technical field of medical data processing, in particular to a method for quickly evaluating thyroid stimulating hormone value, which comprises the following steps: S1, clinical data acquisition; S2, data quality control and feature construction; S3, double-task joint prediction; S4, age self-adaptive reference interval correction; and S5, output of explainable report. The present application compresses the TSH evaluation period from the traditional 2-4 hours to within 5 minutes, reduces the detection cost by about 80%, and greatly improves the accessibility of thyroid function abnormality screening.

Provided are: a transthyretin tetramer stabilizing agent; and a transthyretin amyloidosis preventing agent or progression suppressing agent.　The present invention relates to a transthyretin tetramer stabilizing agent containing a Glycyrrhiza glabra hydrophobic extract that includes Glycyrrhiza-glabra glabra polyphenol, and also to a transthyretin amyloidosis preventing agent or progression suppressing agent containing a Glycyrrhiza glabra hydrophobic extract that includes Glycyrrhiza-glabra glabra polyphenol.

The present disclosure provides methods and a device for thyroxine delivery. This device is designed for subcutaneous implantation to ensure continuous delivery of thyroxine. It features a reservoir regulated by an embedded microprocessor with advanced signal software. The software triggers a precision pump to release a specific dose of thyroxine at regular intervals. This system enhances patient compliance and maintains optimal metabolic control.

The utility model discloses a thyroid function detection assembly. The thyroid function detection assembly comprises a whole blood separation piece and at least one piece of detection test paper, the whole blood separation part is used for filtering red blood cells in blood; the detection test paper comprises a sample receiving end and a detection part, the whole blood separation part is connected with the sample receiving end, and the detection part is used for detecting the concentration of one of thyroid stimulating hormone, free triiodothyronine and free thyroxine. According to the thyroid function detection assembly, the thyroid function can be detected, during detection, the whole blood separation piece can rapidly separate red blood cells in blood within a short time, the rest of the separated blood can enter the detection test paper, detection can be completed by observing the detection part, the blood does not need to be centrifuged into serum, and the detection efficiency is improved. Direct detection of the whole blood sample can be realized, the detection cost is lower, the operation is simple and convenient, the detection time is greatly saved, and the detection efficiency is improved.